Type B - NewAmsterdam Pharma Company N.V. (NAMS) 20260815 Stock Analysis

📅 NewAmsterdam Pharma Key Upcoming Events

• October 22, 2026 Q3 2026 Earnings Release (Estimated)
  • Description: The market will heavily scrutinize the company’s cash burn rate, the trajectory of its research and development expenses, and any updates to the anticipated launch timelines in Europe following the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP).
• December 2026 Topline Data from RUBENS Phase 3 Trial (Estimated)
  • Description: The company is expected to release critical topline efficacy and safety data evaluating obicetrapib alone and in combination with ezetimibe in patients with type 2 diabetes or metabolic syndrome, potentially unlocking a massive adjacent market for cardiovascular risk reduction.
• February 2027 PREVAIL Cardiovascular Outcomes Trial Interim Analysis (Estimated)
  • Description: A highly anticipated data safety monitoring board (DSMB) interim readout for the PREVAIL cardiovascular outcomes trial (CVOT). This event serves as a massive binary catalyst that will either validate or completely destroy the thesis that obicetrapib significantly reduces major adverse cardiovascular events (MACE).
• March 2027 European Commission Decision on Marketing Authorization (Estimated)
  • Description: Following the July 2026 positive CHMP opinion, the European Commission is expected to formally approve Ubeslo (obicetrapib monotherapy) and Evlarco (fixed-dose combination), officially transitioning NewAmsterdam Pharma from a clinical-stage biotechnology firm into a commercial-stage entity via its partner, the Menarini Group.

🏢 Step 1: NewAmsterdam Pharma Company Overview & Business Model

Q1-A1. What is NewAmsterdam Pharma?

• Company Name (Ticker): NewAmsterdam Pharma Company N.V. (NAMS)
• Sector: Healthcare
• Exchange: NASDAQ
• Founded: June 10, 2022 (transitioned to public entity November 2022)
• Listing Date: November 22, 2022
• Fiscal Year End: December
• Headquarters: Netherlands, Naarden
• CEO: Michael H. Davidson, M.D. ※ Founder status: Y
• Market Cap: $3.16B
• Shares Outstanding: 119.54M
• Current Price: $26.67
• Annual Dividend Yield: ➖ Not applicable
• Ex-dividend Date: ➖ Not applicable
• As-of: August 15, 2026 (ET)

Q1-A2. How Does NewAmsterdam Pharma Make Money?

• Core Business Model and Therapeutic Focus: NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company that currently does not generate commercial product revenue from direct sales to patients or providers. The company’s entire enterprise value is built around the research, development, and eventual commercialization of its lead asset, obicetrapib. Obicetrapib is an investigational, highly selective, once-daily oral cholesteryl ester transfer protein (CETP) inhibitor designed to lower low-density lipoprotein cholesterol (LDL-C) and prevent major adverse cardiovascular events (MACE).
• Current Revenue Generation Mechanism: At this pre-commercial stage, capital inflows are strictly derived from strategic out-licensing agreements. The company monetizes its intellectual property by selling regional commercialization rights to larger, established pharmaceutical partners. The most prominent example is the massive commercialization deal struck with the Menarini Group in 2022.
• The Menarini Partnership Structure: Under this agreement, Menarini holds the exclusive rights to commercialize obicetrapib in Europe, either as a monotherapy or as a fixed-dose combination with ezetimibe. In exchange, NewAmsterdam Pharma received an upfront payment of €115 million, committed R&D funding of €27.5 million, and remains eligible for up to €863 million in potential clinical, regulatory, and commercial milestones. Furthermore, upon successful commercialization, NewAmsterdam will collect tiered double-digit percentage royalties ranging from the teens to the mid-twenties on net sales of the drug in Europe.

Q1-A3. NewAmsterdam Pharma’s Revenue Segments & Core Income Sources

• Licensing, Supply, and Milestone Revenue (100%): All currently recognized revenue stems exclusively from supply agreements and milestone payments under the exclusive license agreement with the Menarini Group. For instance, in the second quarter of 2026, the company recognized $3.7 million in revenue, which was entirely related to its supply agreement with Menarini. This segment is highly erratic; for comparison, the company logged $19.1 million in the same quarter of the prior year due to a specific, non-recurring €16.1 million development cost contribution installment.
• Commercial Product Sales (0%): Obicetrapib is currently investigational and remains unapproved for commercial sale in any jurisdiction. Consequently, the company operates at a total commercial deficit while bearing immense clinical trial costs to push its Phase 3 pipeline toward global regulatory approvals.

Q1-A4. Who Are NewAmsterdam Pharma’s Competitors?

• First Mover and Legacy Interventions (Direct Competitors): Deeply entrenched, highly affordable generic statins (such as atorvastatin and rosuvastatin) absolutely dominate the foundational lipid-lowering market and represent the primary first-line standard of care globally. Obicetrapib is primarily positioned as an adjunct therapy for patients who cannot achieve their LDL-C goals on maximally tolerated statins alone.
• Injectable PCSK9 Inhibitor Biologics (Direct Competitors): Amgen’s Repatha (evolocumab) and Novartis’s Leqvio (inclisiran) are highly efficacious biologic therapies that severely lower LDL-C. However, these therapies face structural headwinds related to high costs, restrictive insurance reimbursement friction, and significant patient resistance to subcutaneous injections.
• Oral Non-Statins (Direct Competitors): Esperion Therapeutics’ Nexletol (bempedoic acid) targets the exact same statin-intolerant and inadequately controlled patient population with a daily oral pill, serving as the most direct functional competitor to obicetrapib in the oral adjunct space.
• Disrupted Victim: Injectable PCSK9 inhibitors stand to lose significant market share if obicetrapib successfully proves it can deliver comparable LDL-C reductions (up to 49% when combined with ezetimibe) through a highly convenient, once-daily oral pill. The ability to achieve biologic-like efficacy without the compliance and convenience barriers of injectables would severely disrupt the current treatment algorithm.
• Strategic Position (Differentiated Fast Follower): NewAmsterdam is a highly differentiated fast follower in the historically troubled CETP inhibitor class. First-generation CETP drugs like Pfizer’s torcetrapib failed disastrously due to off-target toxicity, including severe blood pressure spikes and increased mortality. Later iterations like Merck’s anacetrapib showed cardiovascular benefits but accumulated dangerously in adipose (fat) tissue due to high lipophilicity, leading to its abandonment. NewAmsterdam specifically engineered obicetrapib to be highly selective and hydrophilic, effectively avoiding tissue accumulation and blood pressure spikes while maximizing the reduction of atherogenic apolipoprotein B (ApoB) and LDL-C.

Q1-A5. What Problem Does NewAmsterdam Pharma Solve?

• Pain Point: Millions of patients suffering from atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) cannot reach safe LDL-C targets on maximally tolerated statins alone. Furthermore, a significant subset of the population suffers from debilitating statin intolerance (characterized by severe muscle pain or myopathy), leaving them dangerously exposed to fatal cardiovascular events without viable, affordable oral alternatives.
• Solution: Obicetrapib provides a highly potent, well-tolerated, once-daily oral tablet that dramatically lowers LDL-C by inhibiting the transfer of cholesteryl esters from high-density lipoprotein (HDL) to ApoB-containing lipoproteins, thereby upregulating hepatic LDL receptors to clear cholesterol from the blood. This mechanism delivers profound efficacy without the adverse side effects of statins or the painful, inconvenient administration of injectable PCSK9 inhibitors, fundamentally democratizing access to severe lipid reduction.

Q1-A6. NewAmsterdam Pharma Key Milestones: Past 12 Months

• August 05, 2026 Q2 2026 Earnings Release
  • Description: The company reported a net loss of $64.1 million and ended the quarter with $678.3 million in cash, cash equivalents, and marketable securities, underscoring heavy R&D investments to support clinical progression and commercial readiness.
• July 30, 2026 Presented Positive Alzheimer’s Disease Biomarker Data from BROADWAY Trial
  • Description: A prespecified analysis demonstrated that obicetrapib significantly reduced absolute levels of plasma p-tau217 by 20.5% in high-risk APOE4/E4 carriers compared to placebo over 12 months, suggesting CETP inhibition could offer upstream neuroprotective benefits for Alzheimer’s disease prevention.
• July 24, 2026 Received Positive CHMP Opinion for Ubeslo and Evlarco
  • Description: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) officially recommended marketing authorization for obicetrapib monotherapy (Ubeslo) and fixed-dose combination therapies (Evlarco), representing a massive regulatory de-risking event for European commercialization.
• June 11, 2026 USPTO Issued New Composition of Matter Patent for Obicetrapib
  • Description: The United States Patent and Trademark Office granted U.S. Patent No. 12,006,305, a third-generation patent covering amorphous obicetrapib hemicalcium. This critical legal victory extends obicetrapib’s intellectual property protection and exclusivity in the United States until July 2043, effectively neutralizing near-term generic competition concerns.
• March 02, 2026 CEO Executed Major Insider Sale of Shares
  • Description: Chief Executive Officer Michael H. Davidson exercised stock options and subsequently sold 443,707 ordinary shares on the open market at $33.25 per share, resulting in gross proceeds of approximately $14.75 million.

Q1-A7. Step 1 Key Takeaways

• Step 1 Summary: NewAmsterdam Pharma is a highly focused, late-stage biopharmaceutical entity built entirely around a single, highly promising oral CETP inhibitor. While the company boasts stellar clinical efficacy data across its Phase 3 pipeline and strong European distribution partnerships, it operates at a massive deficit and is entirely dependent on upcoming cardiovascular outcomes data to justify its multi-billion-dollar valuation.
• Top 3 Red Flags:
  • 1 Extreme pipeline concentration risk: the company’s entire $3.16 billion valuation hinges on the regulatory and commercial success of a single molecule, obicetrapib, leaving zero margin for error.
  • 2 Aggressive cash burn driven by expensive Phase 3 clinical trials and pre-commercial scale-up, resulting in a staggering $64.1 million net loss in the most recent quarter.
  • 3 High insider selling volume over the past twelve months, highlighted by a $14.75 million stock liquidation by the CEO, raising questions regarding absolute executive conviction ahead of binary data readouts.
• Top 5 Key Financial/Operational Indicators for Next-Level Analysis:
  • 1 The outcomes of the PREVAIL cardiovascular trial (specifically the reduction in MACE), which serves as the ultimate arbiter of commercial viability.
  • 2 Cash runway longevity relative to anticipated FDA and EMA approval and launch timelines.
  • 3 Clinical differentiation of LDL-C and Lp(a) reduction metrics against competing oral non-statins like bempedoic acid.
  • 4 Progression of adjacent exploratory indications, including early Alzheimer’s disease and metabolic syndrome.
  • 5 Menarini milestone payments and royalty mechanics governing European distribution revenue.
• Top 3 Unconfirmed and Estimated:
  • 1 The ultimate U.S. pricing strategy and payer formulary placement for obicetrapib upon FDA approval.
  • 2 The exact timeline for the U.S. New Drug Application (NDA) filing, which trails the European regulatory timeline.
  • 3 The actual real-world adoption rate by cardiologists who may harbor lingering historical bias against the previously toxic CETP inhibitor drug class.

🌲 Step 2: NewAmsterdam Pharma’s Economic Moat, Market Size & Scalability

Q2-A1. Does NewAmsterdam Pharma Have a Durable Economic Moat?

• Technology and Data Monopoly Analysis: NewAmsterdam’s primary economic moat is constructed entirely upon robust, third-generation intellectual property. In June 2026, the USPTO granted a critical composition of matter patent protecting amorphous obicetrapib hemicalcium through July 2043. This effectively creates a multi-decade legal monopoly, pushing the expiration date more than nine years beyond previous second-generation patents. This deep technological moat prevents generic encroachment and protects the specific, highly selective molecular structure that allows obicetrapib to avoid the toxicity of failed predecessors like torcetrapib.
• Network Effects and Scalability Analysis: As a therapeutics company, traditional network effects are non-existent. The value of the drug scales entirely through physician adoption guidelines, clinical trial publications, and payer formulary placements, requiring massive upfront capital to scale awareness rather than benefiting from organic user-to-user growth.
• Switching costs: Switching costs for daily oral medications are inherently low for patients. However, if obicetrapib proves to be the only oral drug capable of bridging the gap to target LDL-C levels without injecting biologics, the psychological resistance to switching back to painful injectables or less effective statins will generate high adherence retention.
• Strong fandom and satisfaction (NPS) verification: Clinical trial retention and adverse event rates act as a reliable proxy for patient satisfaction in the biotech sector. In the pivotal 52-week BROOKLYN trial, the treatment discontinuation rate in the obicetrapib arm was only 7.6% compared to a much higher 14.4% in the placebo group. This heavily implies that the drug is well-tolerated and patients are satisfied with the lack of severe side effects, particularly the absence of muscle pain associated with statins.
• Future pricing power outlook: The company possesses moderate pricing power. While it can undercut the exorbitant costs of injectable PCSK9 inhibitors to gain formulary access, it must remain competitive with other oral non-statins like Nexletol. Peak pricing power will only materialize if the PREVAIL trial proves obicetrapib decisively reduces actual cardiovascular mortality, rather than simply improving biomarker numbers.

Q2-A2. How Big Is NewAmsterdam Pharma’s Market? (TAM)

• TAM (Total Market): The global cardiovascular disease and dyslipidemia market is astronomical, currently encompassing tens of millions of high-risk patients. Analysts at GlobalData explicitly estimate that obicetrapib sales could reach a staggering $1.4 billion by 2032 across just seven key global markets (the US, France, Germany, Italy, Spain, UK, and Japan).
• CAGR (Market Growth Rate): The global lipid-lowering market is expanding steadily due to aging global populations, rising obesity rates, and increasingly stringent medical guidelines demanding lower LDL-C targets, with expected industry CAGRs hovering in the mid-to-high single digits.
• Upside Potential: With a current market capitalization of $3.16 billion and peak sales potentially exceeding $1.4 billion annually, the company is trading at approximately 2.25x peak forward sales, indicating substantial room for equity appreciation if it secures a dominant market share and achieves widespread payer coverage.

Q2-A3. How Real Is NewAmsterdam Pharma’s TAM? (Quality Check)

• Willingness to Pay (WTP): The market for cardiovascular risk reduction is a proven, high-margin ecosystem. Payers and national health systems are highly motivated to cover preventive oral therapies that demonstrably reduce the astronomical hospitalization and surgical costs associated with severe heart attacks, strokes, and coronary revascularization.
• Market Structure: The lipid-lowering market is highly bifurcated, ranging from commoditized generic statins at the absolute bottom to premium-priced biologic injectables at the top. Obicetrapib is perfectly positioned in the “missing middle” as a premium oral therapeutic, bridging the efficacy gap without the delivery burden of a biologic.
• Regulation/Entry Barriers: Regulatory barriers are exceptionally high in cardiovascular medicine. Competitors cannot simply prove biomarker reduction; they must endure agonizing, multi-year, multi-thousand-patient cardiovascular outcomes trials (CVOTs) to definitively prove long-term safety and efficacy, establishing an immense protective barrier against new market entrants.

Q2-A4. Can NewAmsterdam Pharma Keep Expanding Its Market?

• Penetration rate: The current commercial penetration is zero, as the drug is still unapproved. However, the theoretical ceiling is vast; clinical data suggests that upwards of 70% of high-risk ASCVD patients fail to reach their strictly guideline-directed LDL-C targets on statins alone, providing an immediate, massive addressable patient pool.
• Structural Scalability: Scalability is massive. Obicetrapib is formulated as an easily manufactured, highly stable oral small-molecule tablet, allowing for rapid global supply chain deployment without the complex, expensive cold-chain logistics required for biologic injectables like Repatha.
• Zero Marginal Cost: While fundamentally different from a software company, the marginal cost of producing an additional small-molecule tablet is infinitesimally small once the massive R&D and manufacturing fixed costs are recovered, creating exceptional operating leverage at scale.

Q2-A5. Step 2 Key Takeaways

• Scoring Rationale:
  • Economic Moat (8/10): Fortified by a rock-solid, newly issued composition of matter patent extending through 2043, granting a massive legal monopoly, though the moat remains theoretical until commercial approval is secured.
  • Market Size (5/5): The total addressable market for ASCVD and statin-intolerant patients is one of the largest in global medicine, supporting unquestionable blockbuster revenue potential.
  • Market Quality·Profitability (6/7): High willingness to pay from insurers to prevent cardiovascular events, tempered slightly by aggressive pricing competition from ubiquitous generic statins.
  • Market Penetration·Scalability (7/8): Oral tablets scale globally with extreme logistical ease, offering a massive structural advantage over competing PCSK9 injectables requiring cold-chain distribution.
• 📊 Step 2 Score: 26/30 pts (Economic Moat 8/10 + Market Size 5/5 + Market Quality·Profitability 6/7 + Market Penetration·Scalability 7/8)
• Step 2 Summary: NewAmsterdam Pharma boasts excellent intellectual property protection through 2043 and targets a massive, high-quality cardiovascular market, positioning obicetrapib for seamless, highly profitable global scalability upon regulatory approval.

🚀 Step 3: How Fast Is NewAmsterdam Pharma Growing? Hyper-Growth Metrics

Q3-A1. How Fast Is NewAmsterdam Pharma Growing? (Revenue Trajectory)

• Check J-Curve: The company is pre-commercial and does not possess a traditional revenue J-Curve. Total revenue for Q2 2026 was $3.7 million, down dramatically from $19.1 million in Q2 2025. This revenue consists purely of erratic, non-recurring supply agreements and milestone payments from its partner Menarini, rather than sustainable, compounding commercial sales.
• Acceleration: Revenue growth is deeply negative year-over-year (-81%) due entirely to the lumpiness of milestone recognition. True commercial growth and trajectory acceleration cannot be mathematically measured until European and U.S. product launches commence following regulatory approvals.

Q3-A2. NewAmsterdam Pharma’s Key Growth Metrics

• Biotech/Drug Platforms: Clinical Pipeline Efficacy and Advancement
  • Description: For a pre-revenue biopharmaceutical company, intrinsic growth is strictly measured by clinical efficacy readouts, biomarker improvements, and pipeline de-risking. NewAmsterdam has delivered overwhelming, statistically significant growth in clinical validation across its Phase 3 programs. In the Phase 3 BROOKLYN trial (HeFH patients), obicetrapib achieved a 36.3% placebo-adjusted reduction in LDL-C at day 84, sustained at 41.5% at day 365, alongside a 45.9% reduction in lipoprotein(a). In the Phase 3 BROADWAY trial (ASCVD/HeFH), it drove a 33% reduction in LDL-C. Most impressively, in the TANDEM trial, the fixed-dose combination of obicetrapib with ezetimibe drove a massive 49% reduction in LDL-C compared to placebo. Furthermore, an exploratory analysis of the BROADWAY trial hinted at a 21% relative reduction in major adverse cardiovascular events (MACE), providing profound fundamental value growth that completely de-risks the asset ahead of the definitive PREVAIL CVOT trial.

Q3-A3. Are NewAmsterdam Pharma’s Unit Economics Improving?

• Gross Margin: ➖ Not applicable: The company is pre-commercial and does not yet have an established cost of goods sold (COGS) metric for commercial pharmaceutical sales to evaluate gross margin expansion.
• Rule of 40: ➖ Not applicable: The company generates heavy negative free cash flow (-$143.7 million TTM) and negative sustained revenue growth, making this metric mathematically irrelevant at this lifecycle stage.
• LTV / CAC: ➖ Not applicable: Customer acquisition costs and patient lifetime value cannot be calculated until an active commercial sales force is deployed post-FDA approval.

Q3-A4. Step 3 Key Takeaways

• Scoring Rationale:
  • Revenue Growth Acceleration (2/12): Revenue remains purely milestone-driven, exhibiting sharp year-over-year declines with zero commercial product sales to evaluate.
  • Sector-Specific Growth Metrics (10/10): Exceptional, flawless execution of Phase 3 clinical trials, delivering overwhelming LDL-C and Lp(a) reduction efficacy across BROOKLYN, BROADWAY, and TANDEM, completely validating the scientific premise.
  • Unit Economics·Margin (2/8): Pre-commercial status renders unit economics and margin expansion fundamentally unprovable at this time.
• 📊 Step 3 Score: 14/30 pts (Revenue Growth Acceleration 2/12 + Sector-Specific Growth Metrics 10/10 + Unit Economics·Margin 2/8)
• Step 3 Summary: While the company completely fails traditional financial growth metrics due to its pre-commercial status, its clinical pipeline advancement—the true proxy for fundamental biotech growth—has been executed with flawless precision and overwhelming therapeutic efficacy.

💪 Step 4: NewAmsterdam Pharma’s Profit Potential & Free Cash Flow

Q4-A1. Can NewAmsterdam Pharma Turn Growth Into Profit?

• Margin Trajectory: Operating expenses are expanding violently as the company scales its clinical infrastructure. Research and Development (R&D) expenses surged to $41.7 million in Q2 2026, up significantly from $27.5 million in the prior year, driven by the initiation of new clinical trials and increased personnel costs. Meanwhile, Selling, General and Administrative (SG&A) expenses held steady at $26.9 million. The widening operating deficit proves that scalability has not yet translated into financial leverage.
• Entering the Profit and Margin Expansion (BEP & Margin Expansion): The company remains deeply unprofitable, posting a net loss of $64.1 million in Q2 2026. Break-even will entirely depend on the successful commercial launch of obicetrapib. Because the company must fund massive commercialization and marketing efforts ahead of the launch, profitability is strictly gated behind a multi-year horizon and binary regulatory approvals.

Q4-A2. Does NewAmsterdam Pharma Generate Free Cash Flow?

• FCF Generation Power: The company rapidly burns cash to sustain its vast clinical trial network, generating a trailing twelve-month Free Cash Flow (FCF) of negative $143.7 million. There is zero intrinsic cash generation outside of partner milestone drops.
• Self-Funding: NewAmsterdam is incapable of self-funding its operations organically through sales. However, it boasts a formidable, fortress-like balance sheet with $678.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026. This provides an extensive, multi-year runway to survive the clinical trial phase, fund the PREVAIL CVOT, and prepare for a U.S. launch without the immediate threat of highly dilutive secondary equity offerings.

Q4-A3. Step 4 Key Takeaways

• Scoring Rationale:
  • Operating Leverage·Path to Profit (2/8): Net losses are violently expanding as R&D spending accelerates for Phase 3 trials and pre-commercial marketing readiness.
  • FCF·Capital Efficiency (4/7): Heavy free cash flow burn is necessary for clinical trials, but the massive $678.3 million cash reserve demonstrates excellent prior capital raising efficiency and neutralizes short-term dilution risk.
• 📊 Step 4 Score: 6/15 pts (Operating Leverage·Path to Profit 2/8 + FCF·Capital Efficiency 4/7)
• Step 4 Summary: NewAmsterdam Pharma exhibits the massive cash burn and heavy operating losses characteristic of late-stage biotechs, though its fortress balance sheet completely neutralizes near-term survival risks and secures the pathway to commercialization.

👔 Step 5: NewAmsterdam Pharma Management & Shareholder Alignment

Q5-A1. Who Leads NewAmsterdam Pharma? (Founder & Management)

• Founder-Led: Dr. Michael H. Davidson, M.D., serves as the Chief Executive Officer. He co-founded the entity alongside Dr. John Kastelein, securing top-tier leadership driven by the foremost global experts in clinical lipidology. Prior to NewAmsterdam, Dr. Davidson successfully founded and sold Omthera Pharmaceuticals to AstraZeneca for $443 million, and Corvidia Therapeutics to Novo Nordisk, proving his exceptional pedigree in biotech value creation.
• Vision: Dr. Davidson and Dr. Kastelein’s vision extends far beyond a single lipid-lowering drug; they envision obicetrapib fundamentally shifting the global paradigm of preventative cardiovascular care, as evidenced by ongoing, highly successful expansions into Alzheimer’s disease (demonstrating significant p-tau217 biomarker reductions) and metabolic syndrome trials.
• Guidance Hit Rate: Management has executed flawlessly against their clinical guidance, consistently delivering Phase 3 BROOKLYN, BROADWAY, and TANDEM trial readouts exactly on schedule, completing massive trial enrollments on time, and securing European CHMP positive opinions without regulatory delay.
• Transparency and Consistency Between Words and Actions: The executive team transparently details expected cash burn and regulatory hurdles, maintaining clear and scientifically rigorous communication with the market via extensive medical conference presentations at the American Heart Association (AHA) and the European Atherosclerosis Society (EAS).

Q5-A2. Is NewAmsterdam Pharma’s Management Aligned With Shareholders?

• Skin in the Game: The founders and executives hold substantial equity, tying their wealth directly to the success of the PREVAIL trial and the ultimate commercial launch.
• Insider trading (words and actions match): Over the trailing 12 months, insiders have executed heavy net selling, raising significant concerns. Most notably, CEO Michael Davidson exercised options and sold 443,707 shares on March 2, 2026, for massive gross proceeds of $14.75 million. Additionally, Chief Accounting Officer Louise Kooij sold 105,000 shares for roughly $1.99 million in July 2026. While some selling is expected for tax and diversification purposes, such aggressive liquidation by the CEO ahead of the ultimate binary outcome (the PREVAIL MACE readout) signals a lack of absolute conviction to hold through the volatility.
• Compensation system: Executive compensation is heavily weighted toward stock-based performance awards, aligning their ultimate payout with long-term FDA approval and shareholder value creation, despite the recent insider liquidations.

Q5-A3. Step 5 Key Takeaways

• Scoring Rationale:
  • Founder Management·Vision (7/8): Led by brilliant, world-renowned lipidologists with a history of successful biotech exits, who have executed their clinical pipeline with mechanical precision and absolute transparency.
  • Alignment·Accountability (4/7): Aggressive multi-million-dollar insider selling by the CEO and CAO casts a shadow over short-term alignment, warranting a noticeable penalty.
• 📊 Step 5 Score: 11/15 pts (Founder Management·Vision 7/8 + Alignment·Accountability 4/7)
• Step 5 Summary: The company benefits from brilliant, visionary scientific leadership with a proven track record of biotech success, though aggressive insider selling tempers confidence in executive alignment ahead of critical binary catalysts.

⛵ Step 6: NewAmsterdam Pharma Market Flow & Sentiment

Q6-A1. Analyst Consensus vs NewAmsterdam Pharma Guidance

• The stock is heavily priced for perfection. With a $3.16 billion market capitalization resting entirely on a single asset, any delay in European Commission approval or a slight miss in upcoming clinical data could decimate the valuation. This vulnerability was highlighted following the Q2 2026 earnings release, where a widened net loss and dropping milestone revenues triggered a sharp post-earnings selloff.
• Despite the recent fundamental volatility, analyst consensus remains exceedingly bullish. Multiple Tier-1 investment banks and analysts (including BMO Capital, Citi, and Piper Sandler) maintain reiterated “Buy” ratings and aggressive price targets ranging from $45.00 to $60.00, indicating severe dissonance between institutional analyst optimism and near-term market selling pressure.

Q6-A2. What Is NewAmsterdam Pharma’s Short Interest?

• Institutional Trends: Institutional ownership is incredibly dominant, sitting at 89.89%. Major funds, including Frazier Life Sciences, Bain Capital Life Sciences, and BlackRock hold massive, concentrated positions. However, some institutional de-risking is evident; Jennison Associates recently cut its stake by 21.2% in Q1 2026, offloading 738,818 shares. Conversely, funds like Stempoint Capital aggressively increased their stakes by 147.1%.
• Short Selling Indicators: Short interest is highly elevated, with approximately 9.09 million shares sold short, representing 11.27% of the tradable float. The Days-to-Cover ratio sits at a staggeringly high 16.20 days. This metric provides a quantitative assessment that if the PREVAIL outcomes trial produces overwhelmingly positive data or if the European Commission grants final approval, a violent, sustained short squeeze is highly probable due to the massive days required for short sellers to cover their positions.

Q6-A3. Step 6 Key Takeaways

• Scoring Rationale:
  • Consensus vs Guidance (1/3): The stock is highly vulnerable to downside volatility upon any deviation from flawless execution, as seen in the recent post-earnings selloff, despite overly optimistic analyst targets.
  • Supply·Short Interest (2/2): Elevated short interest against a backdrop of massive, rigid institutional ownership (89.89%) creates the perfect powder keg for a massive short squeeze upon positive catalyst realization.
• 📊 Step 6 Score: 3/5 pts (Consensus vs Guidance 1/3 + Supply·Short Interest 2/2)
• Step 6 Summary: Market sentiment is sharply divided, with unyielding analyst optimism and heavy institutional backing clashing against elevated short interest and aggressive post-earnings market selloffs.

🧨 Step 7: NewAmsterdam Pharma Catalysts & Price Triggers

Q7-A1. What Could Re-Rate NewAmsterdam Pharma Stock? (Next 12 Months)

• Breakeven: ➖ Not applicable: Profitability is mathematically impossible within the next 12 months as the company must massively scale its marketing, manufacturing, and supply chain infrastructure to fund the impending commercial launch.
• New Products/Approvals: The formal European Commission approval of Ubeslo and Evlarco, expected in late 2026 or early 2027 following the CHMP positive opinion, will act as a massive de-risking catalyst. This will officially transform the company into a commercial entity and trigger further milestone payments and eventual royalties via its partner Menarini.
• Major orders: The most explosive catalyst in the company’s entire lifecycle is the PREVAIL cardiovascular outcomes trial interim analysis slated for Q4 2026/Q1 2027. If the DSMB confirms obicetrapib significantly reduces MACE (actual heart attacks and strokes, not just LDL-C biomarkers), the stock will fundamentally re-rate to reflect an unstoppable, multi-billion-dollar blockbuster trajectory. Conversely, failure here destroys the entire thesis.

Q7-A2. NewAmsterdam Pharma’s Estimate Revision Trend

• Analyst revenue estimates remain deeply suppressed for FY2026 (estimated at $28.47 million), reflecting the current lull in European milestone payments. However, forward revenue estimates are aggressively modeled for spectacular, violent triple-digit percentage growth. Consensus pegs FY2027 revenue at $141.02 million (+395% YoY) and FY2028 revenue at $362.51 million (+157% YoY), as analysts confidently model the initiation of European royalties and a massive U.S. commercial launch.

Q7-A3. Step 7 Key Takeaways

• Scoring Rationale:
  • Catalyst Strength (3/3): The upcoming PREVAIL MACE data readout and European Commission approval are monumental, generation-defining binary catalysts that will dictate the entire future of the enterprise.
  • Estimated Trend (2/2): Massive long-term revenue upward revisions are already modeled for 2027 and 2028, reflecting high institutional confidence in the commercial launch trajectory.
• 📊 Step 7 Score: 5/5 pts (Catalyst Strength 3/3 + Estimated Trend 2/2)
• Step 7 Summary: The company is hurtling toward generation-defining clinical and regulatory catalysts that hold the power to completely re-rate the enterprise value within the next 12 months, supported by massive forward revenue growth estimates.

⚖️ Step 8: Is NewAmsterdam Pharma Fairly Valued? Valuation Analysis

Q8-A1. NewAmsterdam Pharma’s Key Valuation Multiples

• PS Ratio: 453.27x (Very Overvalued)
• P/FCF Ratio: ➖ Not applicable
• P/OCF Ratio: ➖ Not applicable
• EV/Sales Ratio: ≈374.64x (Very Overvalued)
• EV/EBITDA Ratio: ➖ Not applicable
• EV/FCF Ratio: ➖ Not applicable
• Forward PE: ➖ Not applicable
• PEG Ratio: ➖ Not applicable
• Scoring Rationale: As a pre-commercial biotech company generating only nominal, non-recurring milestone revenue ($7.1M TTM revenue against a $3.16B market cap), the absolute multiples are astronomically high and mechanically trigger extreme overvaluation alerts across all readable metrics.
• 📌 (1) Axis Q8-A1 Score: -5

Q8-A2. NewAmsterdam Pharma vs Peers: Valuation Comparison

• Multiple selection based on peer comparison:
  • Basis: Sales-based (PSR) metrics are strictly mandated because NewAmsterdam and its direct clinical-stage and newly commercial peers (such as Esperion Therapeutics) operate at persistent deficits, rendering profit-based forward PER or EV/EBITDA indicators mathematically impossible to calculate.
• Calculation of peer-to-peer deviation rate: +26,720.7%
  • 🧮 Calculation Formula: ((453.27 - 1.69) / 1.69) × 100 = +26,720.7%
• Scoring Rationale: When compared directly against Esperion Therapeutics (ESPR), the maker of the competing oral non-statin Nexletol, which trades at a Price-to-Sales ratio of just 1.69x, NewAmsterdam trades at an absurd +26,720% premium. This mathematical extreme signals severe relative overvaluation based purely on current recognized sales.
• 📌 (2) Axis Q8-A2 Score: -5

Q8-A3. What Is NewAmsterdam Pharma Worth in the Future? (Forward Valuation)

• (Not applicable)
• 📌 (3) Axis Q8-A3 Score: ➖

Q8-A3-1. What Growth Hurdle Does the Market Demand From NewAmsterdam Pharma? (Forward Valuation Alternative)

• Scoring Rationale: With minimal revenue and a $3.16 billion market cap, the valuation indicates extreme overheating. The current price is entirely disconnected from present fundamentals and must be fully justified by the flawless commercial launch of obicetrapib, rapid expansion of market share against generic statins, and the absolute success of the PREVAIL outcomes trial. The growth hurdle demanded by the market is astronomically high.
• 📌 (3) Axis Q8-A3-1 Score: -5

Q8-A4. Final Valuation Adjustment

• Scoring Rationale: No exceptional fundamental paradigm shifts exist that are not already mechanically priced into the extreme multiples, barring the binary outcomes of the upcoming clinical trials. Zero adjustment points are warranted.
• 📌 (4) Axis Q8-A4 Score: 0

Q8-A5. Valuation Adjustment Score Calculation

• Calculation Process:
  • (1) Axis (Key Valuation Indicator): -5 pts (Very Overvalued)
  • (2) Axis (Peer-to-peer deviation rate): -5 pts (+26,720.7% vs peers)
  • (3) Axis (Justification of Growth): -5 pts (Valuation excessively high requiring aggressive profit growth to justify the current price)
  • (4) Axis (Final adjustment): 0 pts (No exceptional circumstances applied)
• 📊 Valuation Adjustment Score: A1 (-5) + A2 (-5) + A3 (-5) + A4 (0) = -15 pts
• Commentary: The mechanical valuation framework assigns the maximum possible penalty to NewAmsterdam Pharma. This is an unavoidable characteristic of clinical-stage biotechnology entities, where the current price fundamentally ignores present financial metrics and entirely reflects the discounted mathematical probability of future multi-billion-dollar blockbuster sales.
• Step 8 Summary: The stock trades at an immense mathematical premium relative to current fundamentals, demanding absolute perfection in clinical readouts and regulatory execution to rationalize the valuation.

💀 Step 9: What Are the Risks of NewAmsterdam Pharma? Fatal Risks & Pre-Mortem

Q9-A1. Is NewAmsterdam Pharma Burning Cash & Diluting Shareholders?

• Cash Exhaustion: The company holds a massive war chest of $678.3 million in liquid cash and marketable securities as of Q2 2026. With a trailing cash burn of roughly $143 million per year, the runway easily extends well into 2028 or 2029. This completely insulates the company from immediate bankruptcy risks and provides ample stamina to fund the U.S. commercial launch.
• Dilution: The massive cash reserve means the company is not a habitual diluter. It possesses ample financial stamina to fund its own commercial launch preparations without resorting to desperate, value-destroying secondary equity offerings in the near term.

Q9-A2. Do Competition or Regulation Threaten NewAmsterdam Pharma?

• Intensifying Competition: The lipid-lowering space is a brutally competitive, deeply entrenched ecosystem. Obicetrapib must fight for market share against dirt-cheap, highly effective generic statins, established PCSK9 biologics (Amgen’s Repatha, Novartis’s Leqvio), and rival oral non-statins (Esperion’s Nexletol). This will require massive marketing capital to alter ingrained physician prescribing habits and secure favorable insurance formulary tiers.
• Regulatory Risk: The company’s survival is held hostage by the FDA and EMA. Despite positive CHMP opinions in Europe, any unforeseen safety signal involving liver enzymes, muscle toxicity, or blood pressure in the massive, ongoing 9,500-patient PREVAIL trial could instantly trigger regulatory rejection, echoing the historical failures of the CETP inhibitor class.

Q9-A3. NewAmsterdam Pharma Pre-Mortem: What Could Go Wrong?

• “If the stock price crashed by 70% a year later, what was the reason?” The catastrophic failure of the PREVAIL cardiovascular outcomes trial. If the DSMB interim analysis reveals that despite successfully lowering LDL-C, obicetrapib fails to drive a statistically significant reduction in major adverse cardiovascular events (actual heart attacks and strokes), the commercial viability of the drug will instantly evaporate, destroying the core investment thesis.

Q9-A4. Risk Adjustment Score

• Reason for Scoring: While the company boasts an incredibly robust, multi-year cash runway that eliminates near-term financial distress, it faces absolute, company-ending binary clinical risk surrounding the PREVAIL trial, justifying the maximum penalty within the growing pains tier.
• 📊 Risk Adjustment Score: -10 pts
• Step 9 Summary: Financial dilution risks are negligible due to a fortress balance sheet, but the enterprise relies entirely on high-stakes binary clinical and regulatory outcomes to survive.

🎯 Step 10: NewAmsterdam Pharma Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

• Investment Score Calculation Formula:
  • Step breakdown: S2 (26) + S3 (14) + S4 (6) + S5 (11) + S6 (3) + S7 (5) = 65 pts
  • Steps 2-7 Sum (65 pts) + Valuation Adjustment (-15 pts) + Risk Adjustment (-10 pts) = Investment Score 40 pts
• Investment Score & Rating: 40 pts (F Rating ⛔)
  • Commentary: The severe valuation penalty exacted upon the company’s pre-revenue fundamentals, combined with a significant risk deduction for binary clinical outcomes, mathematically drives the total score down into the lowest tier, reflecting extreme speculative risk that is inherently unsuitable for risk-averse capital.

Q10-A2. Should You Buy NewAmsterdam Pharma? (Recommendation)

• Recommendation: Avoid
  • Commentary: While the scientific premise of obicetrapib is immensely promising and the Phase 3 biomarker data is flawless, the current $3.16 billion valuation demands absolute perfection from upcoming binary trial readouts. Investors should remain entirely on the sidelines until the PREVAIL MACE outcomes data structurally de-risks the asset.

Q10-A3. Investment Thesis in One Line

• NewAmsterdam Pharma possesses a highly promising, potentially disruptive oral CETP inhibitor with massive peak sales potential in the cardiovascular space, but extreme pre-commercial valuation multiples and total dependence on upcoming binary clinical outcomes demand an Avoid rating until the PREVAIL trial results definitively de-risk the investment.

Q10-A4. NewAmsterdam Pharma’s Price Trend & Key Drivers

• Stock Price Trend Over the Past 12 Months: Sideways movement ➡️
• March 02, 2026 CEO Liquidated Massive Equity Position
  • Description: Chief Executive Officer Michael Davidson exercised options and sold 443,707 shares for $14.75 million on the open market, injecting uncertainty regarding executive conviction ahead of major clinical readouts. ➡ Downward Pressure
• June 11, 2026 USPTO Granted Composition of Matter Patent to 2043
  • Description: Securing deep intellectual property protection completely eliminated fears of early generic encroachment, drastically expanding the drug’s long-term commercial runway and protecting its unique molecular structure. ➡ Stock Price Stability
• July 24, 2026 Positive CHMP Opinion for European Commercialization
  • Description: European regulatory authorities formally recommended the approval of obicetrapib monotherapy and fixed-dose combinations, clearing the primary hurdle for European market entry via partner Menarini. ➡ Upward Momentum
• August 05, 2026 Q2 2026 Earnings Delivered Heavy Financial Losses
  • Description: The company reported a massive $64.1 million net loss alongside plummeting milestone revenue, violently reminding the market of the immense cash burn required to sustain clinical operations, sparking a sharp 20% selloff. ➡ Stock Price Decline

Q10-A5. Action Plan

• ⚠️ Since the Investment Score for the analyzed company is 40 pts and the Recommendation falls under Avoid, this Action Plan section is omitted as the stock is not suitable for investment.

🕵️‍♂️ Deep Dive Analysis

• ⚠️ Since the Investment Score for the analyzed company is 40 pts and the Recommendation falls under Avoid, this Deep Dive section is omitted as the stock is not suitable for investment.